A carregar...
Dramatic response of refractory metastatic squamous cell carcinoma of the skin with cetuximab/pembrolizumab
Cutaneous squamous cell carcinoma (cSCC) accounts for 20% of skin cancers. At an advanced stage the prognosis is poor, making cSCC the second leading cause of death from skin cancer. In cases of metastatic or unresectable disease, anti-programmed cell death 1 (anti-PD1) treatment has shown promising...
Na minha lista:
| Publicado no: | Ther Adv Med Oncol |
|---|---|
| Main Authors: | , , , , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
SAGE Publications
2021
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC8170330/ https://ncbi.nlm.nih.gov/pubmed/34104225 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1177/17588359211015493 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|